The effect of ivermectin and fluoxetine on the amelioration of mild covid-19 patients

The effect of combined regimen of ivermectin and fluoxetine on the prevention of hospitalization and amelioration of symptoms in mild covid-19 patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220827055798N1

Enrollment

144

Registered

2022-10-07

Start date

2022-09-23

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. Acute upper respiratory infections of multiple and unspecified sites

Interventions

Intervention 1: Ivermectin group: in this group, in addition to the standard treatment, participants in this group will receive daily doses of ivermectin according to their weight range (48 to 50 kg,

51 to 80 kg, 12 mg

and >80 kg, 0.2 mg/kg). Intervention 2: Fluoxetine intervention group: in this group, in addition to the standard treatment, the participants in this group will receive 20mg capsules daily. Interventi

and >80 kg, 0.2 mg/kg) daily. Intervention 4: Control group: Participants in this group will receive only standard treatment according to the guidelines of the Ministry of Health.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: positive covid-19 PCR Completion of the informed consent questionnaire

Exclusion criteria

Exclusion criteria: Taking any SSRI for 10 days before the onset of clinical symptoms and going to the clinic History of mental illnesses Inability or unwillingness to continue studying The need for oxygen therapy or a history of home oxygen therapy History of chronic kidney and liver diseases Use of warfarin, ACE inhibitor, angiotensin II receptor antagonists Acquired immune system deficiency diseases Pregnancy or breastfeeding9- Malnutrition diseases Use of macrocyclic lactone drug family Use of ivermectin for 7 days before the symptoms of covid-19 Dialysis Participants who have participated in another trial study in the last six months.

Design outcomes

Primary

Measure	Time frame
Hospitalization. Timepoint: before the start of the study and 5 days after the start of the study. Method of measurement: questionnaire.;Development of symptoms. Timepoint: before the start of the study and 5 days after the start of the study. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMajid Damiri

Fasa University of Medical Sciences

fahimeaasadi@gmail.com+98 71 5335 0994

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026